
Medicine and Health
Novel insights from financial analysis of the failure to commercialise plazomicin: Implications for the antibiotic investment ecosystem
N. Wells, V. Nguyen, et al.
Explore the alarming challenges faced by small and medium-sized biotechnology enterprises in developing new antibiotics. This research conducted by Nadya Wells, Vinh-Kim Nguyen, and Stephan Harbarth dives into the commercialization failure of Achaogen’s plazomicin, revealing crucial insights to revitalize investor confidence and support SMEs in the urgent quest for novel antibiotics.
~3 min • Beginner • English
Related Publications
Explore these studies to deepen your understanding of the subject.